The bill would change Medicare Advantage and prescription drug plan payment rules beginning in 2028, including excluding diagnoses from chart reviews and health risk assessments and adjusting benchmarks for favorable selection. It would expedite risk-adjustment audits and appeals, authorize recovery of overpayments, and end the Medicare Advantage quality bonus program after 2028. The bill would require Medicare Advantage and prescription drug plans to reimburse the Department of Veterans Affairs for certain care provided to their enrollees, allow states to enforce Medicare Advantage requirements, and prohibit certain coding-related provider incentives.

FactVote-generated overview; it is not an official CRS summary.